ANL 30.68 Increased By ▲ 1.83 (6.34%)
ASC 14.94 Decreased By ▼ -0.21 (-1.39%)
ASL 23.90 Decreased By ▼ -0.25 (-1.04%)
AVN 92.00 Decreased By ▼ -5.95 (-6.07%)
BOP 9.14 Decreased By ▼ -0.16 (-1.72%)
BYCO 10.25 Decreased By ▼ -0.10 (-0.97%)
DGKC 135.60 Increased By ▲ 0.10 (0.07%)
EPCL 50.00 Increased By ▲ 0.02 (0.04%)
FCCL 24.62 Decreased By ▼ -0.54 (-2.15%)
FFBL 24.25 Decreased By ▼ -0.97 (-3.85%)
FFL 15.60 Decreased By ▼ -0.44 (-2.74%)
HASCOL 10.74 Decreased By ▼ -0.33 (-2.98%)
HUBC 85.20 Increased By ▲ 0.20 (0.24%)
HUMNL 7.35 Decreased By ▼ -0.35 (-4.55%)
JSCL 24.85 Decreased By ▼ -0.90 (-3.5%)
KAPCO 37.85 Increased By ▲ 0.40 (1.07%)
KEL 4.15 Decreased By ▼ -0.02 (-0.48%)
LOTCHEM 14.78 Decreased By ▼ -0.35 (-2.31%)
MLCF 46.60 Decreased By ▼ -0.58 (-1.23%)
PAEL 38.25 Decreased By ▼ -1.15 (-2.92%)
PIBTL 11.80 Decreased By ▼ -0.24 (-1.99%)
POWER 10.50 Decreased By ▼ -0.15 (-1.41%)
PPL 90.55 Decreased By ▼ -0.45 (-0.49%)
PRL 26.10 Decreased By ▼ -0.59 (-2.21%)
PTC 8.95 Decreased By ▼ -0.10 (-1.1%)
SILK 1.40 Decreased By ▼ -0.05 (-3.45%)
SNGP 38.10 Decreased By ▼ -0.65 (-1.68%)
TRG 141.10 Decreased By ▼ -4.60 (-3.16%)
UNITY 31.50 Decreased By ▼ -1.40 (-4.26%)
WTL 1.57 Decreased By ▼ -0.04 (-2.48%)
BR100 4,936 Decreased By ▼ -22.94 (-0.46%)
BR30 25,403 Decreased By ▼ -330.65 (-1.28%)
KSE100 45,865 Decreased By ▼ -100.6 (-0.22%)
KSE30 19,173 Decreased By ▼ -26.07 (-0.14%)
World

China's Clover raises $230mn, plans vaccines for COVID-19 variants

  • The latest round of fund-raising, co-led by Temasek and GL Ventures, an affiliate of Asia-focused private equity Hillhouse Capital, brings Clover's total capital raised in the last 12 months to more than $400 million.
23 Feb 2021

BEIJING: China's Clover Biopharmaceuticals, a developer of coronavirus vaccines, has raised $230 million from investors, including Singapore's state investment firm Temasek Holdings, it said on Tuesday, as it develops vaccines for variants.

Clover, which has been developing a vaccine using an immune response-boosting ingredient made by US-based Dynavax Technologies Corp, plans to start mid- to late-stage clinical trials in the first half of 2021.

In a statement, it said the proceeds of the fund-raising would be used to develop vaccines targeting the virus and other diseases, as well as cancer therapies.

"We are working on broadly protective coronavirus vaccine approaches for variant strains of interest," a spokeswoman said, without identifying the specific strains of SARS-CoV-2 to be targeted by the firm's new candidates.

The latest round of fund-raising, co-led by Temasek and GL Ventures, an affiliate of Asia-focused private equity Hillhouse Capital, brings Clover's total capital raised in the last 12 months to more than $400 million.

Clover said it had also started production planning for potentially hundreds of millions of doses of its COVID-19 vaccine this year.

Its global trial is backed by non-profit group the Coalition for Epidemic Preparedness Innovations (CEPI).